Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 07 Jun 2022
FDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate to severe atopic dermatitis
7 June 2022 - Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy ...
Posted by Michael Wonder on 07 Jun 2022
FDA approves drug for prevention of organ rejection in paediatric recipients of heart and liver transplants
7 June 2022 - The FDA has expanded the use of CellCept (mycophenolate mofetil) to prophylaxis of organ rejection in ...
Posted by Michael Wonder on 07 Jun 2022
Global expert panel publishes guidance on deliberative processes for health technology assessment
7 June 2022 - Value in Health announced today the publication of guidance regarding the establishment or improvement of deliberative ...
Posted by Michael Wonder on 07 Jun 2022
Japan drug maker tests medicine vending machine in train station
4 June 2022 - A Japanese pharmaceutical company has started a trial sale of cold medicine, painkillers and other drugs via ...
Posted by Michael Wonder on 07 Jun 2022
U.S. probes how pharmacies set drug prices as costs rise
7 June 2022 - The U.S. Federal Trade Commission has opened a probe into how big pharmacy benefit managers like ...
Posted by Michael Wonder on 07 Jun 2022
AARP continues fight for lower prescription drug prices
7 June 2022 - Older Americans shouldn’t have to choose between their medication and rent or groceries. ...
Posted by Michael Wonder on 07 Jun 2022
Response to engagement on proposals for the Innovative Medicines Fund
7 June 2022 - NHS England and NICE asked for comments on our proposals for the Innovative Medicines Fund. ...
Posted by Michael Wonder on 07 Jun 2022
Patients to have earlier access to cutting edge treatments on NHS
7 June 2022 - The most promising medicines will be fast-tracked to NHS patients through Innovative Medicines Fund ...
Posted by Michael Wonder on 07 Jun 2022
Sifi announces EMA validation of its marketing authorisation application for Akantior for the treatment of acanthamoeba keratitis
7 June 2022 - Sifi has launched an early access program across European countries in June 2022. ...
Posted by Michael Wonder on 07 Jun 2022
The online Pharmaceutical Schedule gets a refresh
7 June 2022 - PHARMAC's online Pharmaceutical Schedule has had a refresh with new features to improve the user experience. ...
Posted by Michael Wonder on 06 Jun 2022
COVID mRNA vaccines can be quickly updated for new variants. So, where's my Omicron booster?
6 June 2022 - Since Omicron was declared a variant of concern at the end of November, it quickly swept ...
Posted by Michael Wonder on 06 Jun 2022
BioCryst announces Health Canada has authorised Orladeyo (berotralstat), the only oral treatment for the prevention of hereditary angioedema attacks
6 June 2022 - BioCryst Pharmaceuticals today announced that Health Canada has approved oral, once daily Orladeyo (berotralstat) for the ...
Posted by Michael Wonder on 06 Jun 2022
Medigen applies for Australian vaccine approval
7 June 2022 - Medigen Vaccine Biologics has applied to the Australian medicines regulator for provisional approval of its COVID-19 ...
Posted by Michael Wonder on 06 Jun 2022
Novavax faces high stakes FDA review this week that will decide the fate of its COVID vaccine in the U.S.
6 June 2022 - If they endorse the vaccine, the FDA will almost certainly authorise the shot for adults in the ...
Posted by Michael Wonder on 06 Jun 2022
Bristol Myers Squibb withdraws supplemental biologics license application for Reblozyl (luspatercept-aamt) for non-transfusion dependent beta thalassaemia
3 June 2022 - Bristol Myers Squibb today announced that the company has withdrawn a supplemental biologics license application for ...